• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov14
Immutep Ltd. Announces Positive Phase II Trial Results for Eftilagimod Alfa in Soft Tissue Sarcoma
11:07
Oct29
Immutep Ltd. Shows Progress in LAG-3 Immunotherapy
06:49
Sep26
Analyst Storey Covers Healthcare Sector With Focus On Immutep Ltd
05:06
Aug29
Immutep released FY2025 Q4 earnings on August 28 (EST), actual revenue USD 618.59 K, actual EPS USD -0.0873
03:00
Immutep released FY2025 Q3 earnings on August 28 (EST), actual revenue USD 596.03K, actual EPS USD -0.0841
03:00
Immutep released FY2025 Annual Earnings on August 28 (EST), actual revenue USD 3.27 M (forecast USD 3.016 M), actual EPS USD -0.2735 (forecast USD -0.2392)
03:00

Schedules & Filings

Schedules
Filings
Aug28
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 618.59 K, Net Income -12.74 M, EPS -0.0873

Feb26
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 979.06 K, Net Income -6.96 M, EPS -0.0479

Aug29
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 577.35 K, Net Income -7.167 M, EPS -0.059

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More